Blood test may help decide who can benefit from repeat targeted therapy
NCT ID NCT07536113
First seen Apr 19, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study looks at whether a simple blood test (ctDNA) can help doctors decide which patients with metastatic colorectal cancer might benefit from retreatment with a targeted therapy called anti-EGFR. Researchers will collect and analyze data from 250 patients who have already had this blood test as part of another study. The goal is to see if the test results can predict how well the retreatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASST GOM Niguarda
RECRUITINGMilan, Italia, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.